Clinical Trials
24 trialsNCT05853458 2026-04-30
HU-F-AIM
Novartis
Phase 4 Terminated
NCT04116502 2026-04-28
MITHRIDATE
University of Birmingham
Phase 3 Recruiting
NCT06093672 2026-03-25
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT02626715 2024-07-16
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
Phase 2 Completed
NCT01387763 2022-04-27
DALIAH
Odense University Hospital
Phase 3 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT01259856 2019-04-30
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT03515018 2018-05-22
HU
First Affiliated Hospital of Harbin Medical University
Phase 3 Unknown
NCT00055874 2018-05-03
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
Phase 3 Completed
NCT01632904 2017-11-14
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Incyte Corporation
Phase 3 Completed
NCT01949805 2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT00004933 2016-07-04
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02480608 2015-06-24
CML2004
University of Leipzig
Phase 1/2 Completed
NCT00002869 2013-12-19
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005823 2013-12-18
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 3 Completed
NCT00025402 2013-12-18
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002771 2013-08-02
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00083187 2013-07-18
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01645124 2012-07-20
CYTO-PV
Consorzio Mario Negri Sud
Phase 3 Terminated
NCT00002674 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed